You need to enable JavaScript to run this app.
Recon: EMA approves PRIME designations for two gene therapies; Roche pays $7.1B for Roivant, Telavant’s leading IBD drug
Recon
Jason Scott
Global
ReconJason Scott
GlobalReconJason ScottGlobal